About NATi
The Nucleic Acid Therapeutics Initiative (NATi), hosted by A*STAR, is Singapore's national platform dedicated to advancing RNA-based medicines and revolutionising drug and vaccine development. NATi's mission is to establish Singapore as a globally recognised hub of excellence in nucleic acid therapeutics research, clinical translation, and commercialisation.
NATi focuses on key RNA modalities such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA). To drive this vision, NATi is building a biotech-like translational engine focused on asset and technology development spanning discovery to clinical development.
We are actively seeking passionate and committed individuals with deep translational expertise to join us in advancing the next generation of RNA-based therapeutics.
Position Overview
NATi is seeking an accomplished Group Leader, Preclinical Development – Cardiovascular & Metabolic Diseases (CVMD) to establish and lead the preclinical development organisation responsible for advancing RNA therapeutic programmes from target discovery and validation through Preclinical Candidate selection and IND-enabling development.
This is an end-to-end drug discovery and development leadership role requiring demonstrated experience initiating, leading and advancing therapeutic programmes across multiple stages of the discovery pipeline. The successful candidate will integrate target biology, oligonucleotide discovery, translational pharmacology, PK/PD, biomarker strategy, safety assessment and candidate selection into coherent therapeutic development programmes.
The Group Leader will establish the experimental and translational capabilities required to progress CVMD programmes, including in vitro assays, in vivo pharmacology, disease models, PK/PD, biodistribution, translational biomarkers and candidate-selection frameworks. Initial therapeutic areas will include obesity, MASH and broader cardiometabolic diseases, spanning liver, adipose tissue, skeletal muscle and other relevant tissues.
The role will provide scientific and matrix leadership of multidisciplinary project teams across disease biology, oligonucleotide chemistry, delivery, analytical sciences, ADME/PK, bioanalytics and toxicology, ensuring integrated programme execution with clear milestones and evidence-based decisions.
The successful candidate will build and lead a multidisciplinary team supporting multiple parallel pipeline programmes, personally leading selected programmes while developing other scientists into effective Program Leaders.
A significant proportion of specialised studies will be outsourced. The Group Leader will maintain active scientific oversight of CROs and external partners, ensuring study quality, appropriate interpretation, timelines, budgets and delivery against programme objectives.
Job Description
Group Leadership & Pipeline Development
- Establish and lead the CVMD Preclinical Development group, defining its scientific strategy, capabilities, organisational structure and operating model.
- Build an integrated discovery-to-IND workflow supporting multiple RNA therapeutic programmes from target identification through candidate selection and IND-enabling transition.
- Initiate therapeutic programmes from human genetics, disease biology and emerging scientific opportunities, translating hypotheses into executable drug-discovery strategies.
- Develop Target Candidate Profiles, Target Product Profiles and integrated programme plans defining scientific hypotheses, differentiation, critical experiments, milestones and decision criteria.
- Lead selected programmes directly while establishing the capability to manage multiple parallel programmes through other Program Leaders.
- Recruit, develop and mentor multidisciplinary scientists across disease biology, in vitro and in vivo pharmacology and translational science.
- Develop scientists into effective Program Leaders through mentorship in drug-development strategy, cross-functional leadership, project planning and evidence-based decision-making.
- Drive programme prioritisation, resource allocation and go/no-go decisions in partnership with senior leadership.
End-to-End Drug Discovery & Preclinical Development
- Provide scientific and strategic leadership across target identification, target validation, assay development, oligonucleotide screening, lead identification, lead optimisation, candidate selection and IND-enabling preparation.
- Translate biological hypotheses into rigorous experimental strategies addressing target validity, mechanism of action, magnitude and durability of effect, therapeutic window and translational potential.
- Establish fit-for-purpose in vitro and in vivo screening cascades to progressively evaluate target biology, oligonucleotide activity and therapeutic relevance.
- Define Preclinical Candidate selection criteria integrating potency, durability, biodistribution, PK/PD, efficacy, safety, tolerability, manufacturability and translational potential.
- Establish programme-specific biomarker and translational strategies linking target engagement and pharmacodynamic activity to clinically meaningful outcomes.
- Drive programme development readiness in collaboration with toxicology, DMPK, analytical, CMC and regulatory functions, supporting transition into IND-enabling development.
In Vitro, In Vivo & Translational Pharmacology
- Establish and oversee internal and external experimental capabilities spanning in vitro biology, in vivo pharmacology and translational science.
- Develop disease-relevant cellular assays, primary-cell systems and mechanistic models for target validation, oligonucleotide screening and mechanism-of-action studies.
- Design screening cascades evaluating potency, concentration-response, durability, target engagement, functional activity and delivery-dependent pharmacology.
- Select and validate appropriate animal models for obesity, MASH, diabetes, insulin resistance, dyslipidaemia and other cardiometabolic diseases.
- Establish in vivo strategies integrating PK/PD, biodistribution, tissue exposure, target knockdown, pharmacological efficacy and early tolerability.
- Define quantitative exposure-response and knockdown-response relationships to guide dose selection, lead optimisation and candidate progression.
- Integrate pharmacology, bioanalytics, biomarkers, pathology and safety data to establish therapeutic potential and candidate readiness.
- Ensure preclinical models and endpoints provide meaningful translational bridges to clinical development.
Matrix Programme Leadership
- Serve as the scientific and operational leader of multidisciplinary project teams, maintaining accountability for programme strategy, execution and progression.
- Coordinate activities across oligonucleotide chemistry, conjugation and delivery, analytical sciences, bioanalytics, disease biology, pharmacology, ADME/PK, pathology, toxicology, CMC and regulatory functions.
- Translate programme strategy into integrated project plans with defined workstreams, deliverables, timelines, dependencies and decision points.
- Integrate biological, chemical, analytical and translational evidence into lead optimisation and candidate-selection decisions.
- Lead programme reviews and resolve scientific, technical and operational challenges affecting progression.
- Communicate programme strategy, progress, risks and critical decisions to senior management and portfolio governance forums.
Oligonucleotide Drug Discovery
- Provide strategic oversight of siRNA and ASO discovery programmes in collaboration with oligonucleotide chemistry and delivery teams.
- Define biological screening strategies supporting sequence selection, chemistry optimisation and delivery evaluation.
- Integrate target biology, sequence activity, oligonucleotide chemistry, biodistribution and pharmacology to drive lead identification and optimisation.
- Establish screening strategies addressing potency, durability, off-target effects and tissue-specific delivery.
- Partner with chemistry and delivery teams to address extrahepatic delivery challenges, particularly for adipose tissue, skeletal muscle and other therapeutically relevant tissues.
CVMD Disease Biology & Target Discovery
- Provide scientific leadership across cardiometabolic biology, particularly obesity, MASH, metabolic dysfunction and associated cardiovascular disease.
- Integrate human genetics, functional genomics, multi-omics and clinical datasets to identify and prioritise differentiated therapeutic targets.
- Apply strong understanding of liver biology, including lipid metabolism, inflammation, fibrosis and MASH pathophysiology.
- Leverage expertise in obesity, energy balance, adipose biology, endocrine signalling, insulin resistance and metabolic adaptation.
- Apply working knowledge of skeletal muscle metabolism, insulin sensitivity, glucose utilisation and systemic metabolic regulation.
- Integrate liver-adipose-muscle and broader inter-organ crosstalk to identify novel therapeutic opportunities.
- Critically assess target biology, mechanism, tractability, competitive landscape and translational potential before programme initiation.
CRO & External Development Oversight
- Define an externalisation strategy identifying capabilities to establish internally versus those best accessed through CROs and specialised partners.
- Select and oversee CROs supporting pharmacology, PK/PD, bioanalytics, biomarker analysis, pathology, toxicology and specialised disease models.
- Provide active scientific oversight covering study design, protocol review, model selection, endpoint definition and data interpretation.
- Critically evaluate raw and processed data, ensuring scientific quality, reproducibility and appropriate conclusions.
- Maintain accountability for external study timelines, deliverables, budgets and programme dependencies.
- Establish a high-quality external development network that expands NATi's capabilities without unnecessary duplication of internal infrastructure.
Scientific Governance & Organisational Development
- Establish scientific and operational standards for in vitro studies, in vivo pharmacology, PK/PD, biodistribution, bioanalysis and early tolerability.
- Implement fit-for-purpose SOPs, documentation, study-reporting and data-review processes.
- Ensure scientific rigour, reproducibility, data integrity and compliance with animal ethics requirements.
- Establish programme governance and decision frameworks supporting timely, evidence-based progression and termination decisions.
- Build a culture of scientific ownership, accountability, critical thinking and hands-on engagement with experimental data.
- Mentor scientists and Program Leaders to develop an integrated understanding of therapeutic development, from target hypothesis through clinical development readiness.
Qualifications & Professional Attributes
- PhD in Pharmacology, Molecular Biology, Biochemistry, Physiology or a related biomedical discipline.
- 10+ years of pharmaceutical or biotechnology R&D experience in drug discovery and preclinical development, preferably involving RNA or oligonucleotide therapeutics.
- Demonstrated track record initiating and advancing therapeutic programmes from target discovery or validation through lead optimisation and Preclinical Candidate selection, with experience transitioning programmes towards or into IND-enabling development.
- Experience as a Program Leader, Project Team Leader or equivalent matrix leader with accountability for multidisciplinary therapeutic programmes.
- Broad understanding of end-to-end drug discovery and development beyond a single functional discipline.
- Strong experience integrating in vitro biology, in vivo pharmacology, PK/PD, biodistribution, biomarkers and translational strategies into therapeutic programmes.
- Experience establishing screening cascades and evidence packages supporting lead optimisation, candidate selection and go/no-go decisions.
- Deep understanding of siRNA and/or ASO discovery, including oligonucleotide screening, pharmacology, tissue exposure, target knockdown and delivery considerations.
- Strong scientific expertise in cardiovascular and metabolic diseases, particularly obesity, MASH, diabetes and metabolic dysfunction.
- Demonstrated ability to lead matrix teams across oligonucleotide chemistry, analytical sciences, ADME/PK, bioanalytics, toxicology, pathology, CMC and regulatory functions.
- Significant experience designing and overseeing outsourced studies and managing scientific relationships with CROs and external partners.
- Proven ability to establish, recruit and lead multidisciplinary scientific teams.
- Demonstrated ability to mentor and develop scientists into independent Program Leaders.
- Experience managing multiple therapeutic programmes simultaneously, directly or through oversight of other Program Leaders.
Global Recruitment & Competitive Compensation
NATi is conducting a global search for top-tier talent in RNA therapeutics. We welcome applications from leading pharmaceuticals scientists and biotech innovators worldwide.
This role provides a highly competitive compensation package aligned with global industry standards, including attractive benefits and long-term career growth opportunities within Singapore's thriving biomedical innovation ecosystem. Join us in shaping the future of RNA-based medicines and establishing Singapore as a world-class hub for nucleic acid therapeutics.